Aggregated price index with volume information
Summary:
- Pharmaceuticals: Other stocks down 0.8% on average while median return down 1.0% in a day
- Pharmaceuticals: Other stocks up 1.7% on average while median return up -1.0% in a week
- Pharmaceuticals: Other stocks down 5.0% on average while median return down 9.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $ICPT 69.8%, $ACST 34.8%, $BLRX 30.9%, $MDWD 26.8%, $MRNS 14.8%
- 1M losers are : Losers for past month are $OPT -24.3%, $RVNC -35.8%, $SCYX -36.0%, $TNXP -42.0%, $MYSZ -46.7%
- 1W winners are : Winners for past week are $ICPT 76.9%, $ACST 58.2%, $AGRX 37.5%, $EVOK 35.6%, $BPTS 34.8%
- 1W losers are : Losers for past week are $BLRX -12.1%, $CORT -13.9%, $CPIX -16.4%, $SCYX -31.1%, $TNXP -32.9%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 6.4%, for the past 3 months is 4.7%
In the past month for a 5 days rolling window, the highest corrrelation is 21.7%, the lowest correlation is 0.5%, the latest correlation is 0.5%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 57.5% between CRON and CTLT
The lowest correlation is -69.0% between CORT and EVOK
DUBLIN, September 29, 2023--IRISH TAKEOVER PANEL
DUBLIN, September 29, 2023--Horizon Therapeutics announced new data on TEPEZZA (teprotumumab-trbw) and Thyroid Eye Disease (TED) at American Thyroid Association (ATA) 2023.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NASHVILLE, Tenn., September 29, 2023--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from "Harrow Health, Inc." to "Harrow, Inc." to align with the Company’s current five-year strategic plan, which includes an exclusive focus on eyecare pharmaceuticals.
Key Insights Significant control over MediWound by individual investors implies that the general public has more power...
CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 1,248,098 shares of its common stock at a public offering price of $151.69 per share, and, to certain investors, pre-funded warrants to purchase 2,048,098 shares of common stock at a price of $151.6899 per pre-funded war
CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 9,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series A warrants to purchase up to an aggregate of 9,000,000 shares of common stock and Series B war
Shares of Agile Therapeutics (NASDAQ: AGRX) were up more than 23% for the week as of 3 p.m. on Thursday, according to data provided by S&P Global Market Intelligence. The stock got a boost late last week when it got an upgrade from analysts at Maxim Group with a buy rating and a price target of $5. It also helps that the stock appears to have avoided the threat of being delisted from the Nasdaq for now.
CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and, to certain investors, pre-funded warrants to purchase common stock. The purchase price of each pre-funded warrant will equal the price per share at which shares of co